CCL-18在慢性阻塞性肺疾病患者血清中的表达水平及意义
发布时间：2019-03-18 20:22
【摘要】：研究背景 慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是呼吸系统常见病、多发病,它是一种由于慢性支气管炎和肺气肿导致气流受限为特征的可以预防和治疗的肺部疾病,气流受限不完全可逆,呈进行性发展。研究认为,COPD的发病与肺部对香烟、烟雾、废气等有害气体或颗粒吸入所产生的异常炎症有关。据统计,2000年COPD占全球死亡原因的第4位,预计到2020年,COPD将上升为第3位致死原因,且成为全球经济负担的第5位。近年来,慢性阻塞性肺疾病患病率逐年上升,且病死率高,严重影响患者的生活质量及劳动能力,增加家庭及社会的经济负担,已成为一个全球关注的重要公共卫生问题。 COPD发病机制尚未完全阐明,病理表现多样,目前可用于评估慢性阻塞性肺疾病(COPD)患者病情和临床疗效的标志物有限。许多研究者指出在COPD发病过程中,炎症反应起关键作用,多种细胞因子、趋化因子、炎症细胞、粘附分子参与了COPD的发生和发展。有些细胞因子、趋化因子等有可能成为临床评估COPD严重程度的指标,在其发病过程中起重要作用。趋化因子配体-18(CCchemokine ligand-18, CCL-18)属于CC族趋化因子,CCL-18mRNA在肺中持续高水平表达,研究发现其很可能参与机体首次免疫应答,但在COPD中的作用国内还无人研究。白细胞介素-6(Interleukin-6, IL-6)属于前炎症因子,能促进及加重局部炎症反应的发生发展,在COPD的发病中起重要作用。 因此,探寻CCL-18在COPD发展进程中的作用,可以了解其在疾病进程中的作用,以指导临床治疗。 目的 本研究通过测定慢性阻塞性肺疾病急性加重期患者治疗前后血清中CCL-18、IL-6表达水平的变化,并以健康者作对照,测定其与患者肺功能相关性,以IL-6为参照,探讨CCL-18在慢性阻塞性肺疾病患者治疗过程中的临床意义,为判断患者病情严重程度及指导治疗提供依据。 方法 选取2012年7月至2012年9月于郑州大学第一附属医院住院的慢性阻塞性肺疾病急性加重期患者30例,并依据患者年龄、性别选取30例门诊健康体检者作对照组,分别于晨起空腹状态下抽取慢性阻塞性肺疾病急性加重期患者治疗前、后及健康对照组静脉血,离心后应用酶联免疫吸附法检测各组血清中CCL-18、IL-6表达水平的变化,并评价其与患者肺功能的相关性。 结果 慢性阻塞性肺疾病急性加重期患者治疗前、后血清中CCL-18、IL-6含量较健康者明显升高,差异有统计学意义(P0.05)。慢性阻塞性肺疾病急性加重期患者治疗后较治疗前血清中CCL-18、IL-6含量明显降低,差异有统计学意义(P0.05)。血清中CCL-18、IL-6含量与患者肺功能中FEVl占预计值百分比及FEV1/FVC数值呈负相关。CCL-18与IL-6的变化同步。 结论 CCL-18可能参与了慢性阻塞性肺疾病的炎性反应过程。它的检测对判断慢性阻塞性肺疾病患者病情严重程度具有指导意义,可以作为判断COPD患者病情的指标,从而指导临床治疗。
[Abstract]:Study Background Chronic obstructive pulmonary disease (COPD) is a common disease in the respiratory system. It is a kind of lung disease that can be prevented and treated due to the limited air flow caused by chronic bronchitis and emphysema. retrogression The study found that the incidence of COPD and the abnormal inflammation caused by the inhalation of harmful gas or particles such as cigarette, smoke, exhaust gas, etc. According to statistics, in 2000, COPD accounted for 4 of the cause of global death, and it is expected that in 2020, COPD will rise to the third fatal cause and be the fifth of the global economic burden. In recent years, the prevalence of chronic obstructive pulmonary disease has increased year by year, and the fatality rate is high, which seriously affects the quality of life and the labor capacity of the patients, increases the economic burden of the family and society, and has become an important public health question of global concern The pathogenesis of COPD is not yet fully set forth, and the pathological manifestations are diverse and can be used to assess the condition and clinical curative effect of patients with chronic obstructive pulmonary disease (COPD). Many researchers note that inflammatory response plays a key role in the pathogenesis of COPD, and various cytokines, chemokines, inflammatory cells, and adhesion molecules are involved in the occurrence of COPD And development. Some cytokines, chemokines, and the like can be used as an indicator for clinical assessment of the severity of COPD and can be lifted during the course of the disease. The chemokine ligand-18 (CCL-18) is a CC-family chemokine, and the CCLL-18 mRNA is expressed in the lung at a high level. It is found that it is likely to be involved in the first immune response of the body, but the role of the chemokine ligand-18 (CCLL-18) in COPD is not yet available. Human research. Interleukin-6 (Interleukin-6, IL-6) belongs to the pre-inflammatory factors, can promote and aggravate the development of local inflammatory reaction, and can be used for hoisting in the pathogenesis of COPD. It is important to explore the role of CCL-18 in the development of COPD and to understand its role in the process of disease and to refer to its role in the process of disease progression. guide Objective To study the changes of the expression of CCLL-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease. The clinical significance of CCL-18 in the treatment of patients with chronic obstructive pulmonary disease was discussed with the reference of IL-6. and the finger According to the method,30 patients with acute exacerbation of chronic obstructive pulmonary disease were selected from July 2012 to September 2012 in the first affiliated hospital of Zhengzhou University, and 3 cases were selected according to the age of the patient. The changes of the expression of CCLL-18 and IL-6 in the serum of 0 patients with acute exacerbation of chronic obstructive pulmonary disease were detected by enzyme-linked immunosorbent assay (ELISA), and the levels of the expression of CCLL-18 and IL-6 in each group were detected by enzyme-linked immunosorbent assay (ELISA). evaluation The results showed that the levels of CCLL-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease were higher than those in the healthy ones. The content of CCl-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease was significantly lower than that in the pre-treatment group. The difference was significant (P0.05). The contents of CCL-18, IL-6 in serum and FEV1 in the lung function of the patient were 100%. There was a negative correlation between the fractional ratio and the value of FEV1/ FVC. .C CL-18 is synchronized with the change in IL-6. Conclusion CCL-1 8. It may be involved in the inflammatory response of chronic obstructive pulmonary disease. Its detection is of guiding significance to the determination of the severity of chronic obstructive pulmonary disease. It can be used as a judgment.
【学位授予单位】：郑州大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563
本文编号：2443212
[Abstract]:Study Background Chronic obstructive pulmonary disease (COPD) is a common disease in the respiratory system. It is a kind of lung disease that can be prevented and treated due to the limited air flow caused by chronic bronchitis and emphysema. retrogression The study found that the incidence of COPD and the abnormal inflammation caused by the inhalation of harmful gas or particles such as cigarette, smoke, exhaust gas, etc. According to statistics, in 2000, COPD accounted for 4 of the cause of global death, and it is expected that in 2020, COPD will rise to the third fatal cause and be the fifth of the global economic burden. In recent years, the prevalence of chronic obstructive pulmonary disease has increased year by year, and the fatality rate is high, which seriously affects the quality of life and the labor capacity of the patients, increases the economic burden of the family and society, and has become an important public health question of global concern The pathogenesis of COPD is not yet fully set forth, and the pathological manifestations are diverse and can be used to assess the condition and clinical curative effect of patients with chronic obstructive pulmonary disease (COPD). Many researchers note that inflammatory response plays a key role in the pathogenesis of COPD, and various cytokines, chemokines, inflammatory cells, and adhesion molecules are involved in the occurrence of COPD And development. Some cytokines, chemokines, and the like can be used as an indicator for clinical assessment of the severity of COPD and can be lifted during the course of the disease. The chemokine ligand-18 (CCL-18) is a CC-family chemokine, and the CCLL-18 mRNA is expressed in the lung at a high level. It is found that it is likely to be involved in the first immune response of the body, but the role of the chemokine ligand-18 (CCLL-18) in COPD is not yet available. Human research. Interleukin-6 (Interleukin-6, IL-6) belongs to the pre-inflammatory factors, can promote and aggravate the development of local inflammatory reaction, and can be used for hoisting in the pathogenesis of COPD. It is important to explore the role of CCL-18 in the development of COPD and to understand its role in the process of disease and to refer to its role in the process of disease progression. guide Objective To study the changes of the expression of CCLL-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease. The clinical significance of CCL-18 in the treatment of patients with chronic obstructive pulmonary disease was discussed with the reference of IL-6. and the finger According to the method,30 patients with acute exacerbation of chronic obstructive pulmonary disease were selected from July 2012 to September 2012 in the first affiliated hospital of Zhengzhou University, and 3 cases were selected according to the age of the patient. The changes of the expression of CCLL-18 and IL-6 in the serum of 0 patients with acute exacerbation of chronic obstructive pulmonary disease were detected by enzyme-linked immunosorbent assay (ELISA), and the levels of the expression of CCLL-18 and IL-6 in each group were detected by enzyme-linked immunosorbent assay (ELISA). evaluation The results showed that the levels of CCLL-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease were higher than those in the healthy ones. The content of CCl-18 and IL-6 in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease was significantly lower than that in the pre-treatment group. The difference was significant (P0.05). The contents of CCL-18, IL-6 in serum and FEV1 in the lung function of the patient were 100%. There was a negative correlation between the fractional ratio and the value of FEV1/ FVC. .C CL-18 is synchronized with the change in IL-6. Conclusion CCL-1 8. It may be involved in the inflammatory response of chronic obstructive pulmonary disease. Its detection is of guiding significance to the determination of the severity of chronic obstructive pulmonary disease. It can be used as a judgment.
【学位授予单位】：郑州大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R563
【参考文献】
相关期刊论文 前8条
1 刘景艳,修清玉;细胞因子在慢性阻塞性肺疾病发病中的作用[J];国外医学.呼吸系统分册;2005年06期
2 赵庆琪;姚加平;;COPD患者血清IL-6、IL-8、hs-CRP和IL-18检测的临床意义[J];放射免疫学杂志;2012年04期
3 何智辉;陈平;;慢性阻塞性肺疾病患者体内白介素-6和C反应蛋白质量浓度的变化及意义[J];中国实用内科杂志;2006年13期
4 石玉枝;刘豹;霍建民;张薇;;慢性阻塞性肺疾病易感性与白细胞介素1基因的多态性[J];中国临床康复;2006年16期
5 李玉珊;慢性阻塞性肺病合并肺部感染患者IL-6、IL-8、TNF-α测定的临床意义[J];医学文选;2003年05期
6 孙凌;齐云萍;邓洁;王煜;;不同营养状态COPD白细胞介素-6测定及其临床意义[J];医学研究杂志;2008年10期
7 ;慢性阻塞性肺疾病诊治指南(2007年修订版)[J];中华结核和呼吸杂志;2007年01期
8 王健;安新业;张力;董艳;高梅兰;;过敏性哮喘急性发作患儿CCL18水平测定及意义[J];中国实用医药;2011年09期
，本文编号：2443212
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2443212.html
最近更新
教材专著
